Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:21:24 EDT Fri 11 Jul 2025
Enter Symbol
or Name
USA
CA



Q:VYGR - VOYAGER THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VYGR - Q0.13.45·4.120.13.49-0.06-1.7830.02,7463,0763.57  3.615  3.4659.55  2.64519:25:30Jun 1015 min RT 2¢

Recent Trades - Last 10 of 3076
Time ETExPriceChangeVolume
19:25:30Q3.640.0957
17:23:34Q3.49-0.0610,294
16:29:43Q3.49-0.061,919
16:22:36Q3.4504-0.09962,000
16:13:11Q3.55 15
16:04:15Q3.49-0.061
16:04:11Q3.49-0.061
16:04:10Q3.49-0.061
16:04:09Q3.49-0.061
16:04:09Q3.49-0.061

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-10 07:01U:VYGRNews ReleaseVoyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
2025-05-15 07:01U:VYGRNews ReleaseVoyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
2025-05-06 16:01U:VYGRNews ReleaseVoyager Reports First Quarter 2025 Financial and Operating Results
2025-04-28 16:30U:VYGRNews ReleaseVoyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
2025-03-31 07:01U:VYGRNews ReleaseVoyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD(TM) 2025
2025-03-11 16:01U:VYGRNews ReleaseVoyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
2025-03-04 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
2025-03-03 07:00U:VYGRNews ReleaseVoyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease
2025-02-25 07:00U:VYGRNews ReleaseVoyager Therapeutics to Present at Multiple Upcoming Investor Conferences
2025-02-11 07:00U:VYGRNews ReleaseVoyager Provides Update on SOD1 ALS Gene Therapy Program
2025-02-06 07:00U:VYGRNews ReleaseVoyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference
2024-11-20 07:00U:VYGRNews ReleaseVoyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease
2024-11-12 16:01U:VYGRNews ReleaseVoyager Reports Third Quarter 2024 Financial and Operating Results
2024-11-06 07:00U:VYGRNews ReleaseVoyager Therapeutics to Present at Multiple Upcoming Investor Conferences
2024-11-05 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
2024-09-16 07:00U:VYGRNews ReleaseVoyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
2024-09-05 08:00U:VYGRNews ReleaseVoyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
2024-08-29 16:01U:VYGRNews ReleaseVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-29 07:00U:VYGRNews ReleaseVoyager Therapeutics to Present at Multiple Upcoming Investor Conferences
2024-08-07 07:00U:VYGRNews ReleaseVoyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase